Sensor-driven disease detection company Glympse Bio has raised $22 million in a Series A round to fund clinical trials for its technology.
The Cambridge, Mass.-based company uses bioengineered activity sensors transported to the site of disease in patients to investigate biological targets such as proteases – a class of enzymes that drive critical disease pathways. Once a disease is located, the sensor emits a signal that can be detected noninvasively from the recipient’s urine, according to the company.